63 results on '"Stein, Daniel S."'
Search Results
2. Correction for Kovacs et al., “An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline”
3. An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline
4. Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
5. Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
6. A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine
7. Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers
8. Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects
9. Clinical disposition, metabolism and in vitro drug–drug interaction properties of omadacycline
10. Open-Label, Single-Dose, Parallel-Group Study in Healthy Volunteers To Determine the Drug-Drug Interaction Potential between KAE609 (Cipargamin) and Piperaquine
11. A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the antimalarial agents KAE609 and piperaquine (PPQ)
12. Population Pharmacokinetics and Pharmacodynamics of Albinterferon Alfa-2b in Patients Treated for Hepatitis C Virus Genotype 2/3
13. Evaluation of two novel tablet formulations of artemether-lumefantrine (Coartem®) for bioequivalence in a randomized, open-label, two-period study
14. Phase I, Open-Label, Single-Dose Study To Evaluate the Pharmacokinetics and Safety of Telbivudine in Children and Adolescents with Chronic Hepatitis B
15. Sa1031 Mild to Moderate Hepatic Impairment Has No Effect on the Single Dose Pharmacokinetics of Alisporivir (ALV)
16. Population Pharmacokinetics and Exposure-Response of Albinterferon Alfa-2b
17. Dose Range Evaluation of Mycograb C28Y Variant, a Human Recombinant Antibody Fragment to Heat Shock Protein 90, in Combination with Amphotericin B-Desoxycholate for Treatment of Murine Systemic Candidiasis
18. Single-Dose Pharmacokinetics, Safety, and Tolerability of Albinterferon Alfa-2b in Subjects with End-Stage Renal Disease on Hemodialysis Compared to Those in Matched Healthy Volunteers
19. Interaction between Fosamprenavir, with and without Ritonavir, and Nevirapine in Human Immunodeficiency Virus-Infected Subjects
20. Single-Dose Safety and Pharmacokinetics of Brecanavir, a Novel Human Immunodeficiency Virus Protease Inhibitor
21. Effect of Antacids and Ranitidine on the Single-Dose Pharmacokinetics of Fosamprenavir
22. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers
23. In Vitro-In Vivo Model for Evaluating the Antiviral Activity of Amprenavir in Combination with Ritonavir Administered at 600 and 100 Milligrams, Respectively, Every 12 Hours
24. Pharmacokinetic Modeling and Simulations of Interaction of Amprenavir and Ritonavir
25. Clinical Pharmacology and Pharmacokinetics of Amprenavir
26. Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir
27. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers
28. Metabolic Disposition and Pharmacokinetics of [14C]-Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects
29. In Vivo Effect of α 1 -Acid Glycoprotein on Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Protease Inhibitor
30. Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing
31. Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians
32. Multiple-Dose Pharmacokinetics and Pharmacodynamics of Abacavir Alone and in Combination with Zidovudine in Human Immunodeficiency Virus-Infected Adults
33. Population Pharmacokinetics and Pharmacodynamic Modeling of Abacavir (1592U89) from a Dose-Ranging, Double-Blind, Randomized Monotherapy Trial with Human Immunodeficiency Virus-Infected Subjects
34. Direct Measurement of the Anti-Influenza Agent Zanamivir in the Respiratory Tract following Inhalation
35. Pharmacokinetic Interaction of Abacavir (1592U89) and Ethanol in Human Immunodeficiency Virus-Infected Adults
36. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function
37. Pharmacokinetics of [ 14 C]Abacavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitor, Administered in a Single Oral Dose to HIV-1-Infected Adults: a Mass Balance Study
38. Abacavir: Absolute Bioavailability, Bioequivalence of Three Oral Formulations, and Effect of Food
39. THE EFFECT OF PROPHYLAXIS WITH DAPSONE ON DEVELOPMENT OF MYCOBACTERIUM AVIUM-INTRACELLULARE DISEASE
40. Is Amphotericin B Test Dosing Needed?
41. HUMAN PAPILLOMAVIRUS TYPE 16 AND RISK OF PREINVASIVE AND INVASIVE VULVAR CANCER
42. Mathematical Modeling of the Interrelationship of CD4 Lymphocyte Count and Viral Load Changes Induced by the Protease Inhibitor Indinavir
43. Factors Related to Errors in Medication Prescribing
44. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy
45. Comparative Pharmacokinetics and Renal Effects of Cyclosporin A and Cyclosporin G in Renal Allograft Recipients
46. Zidovudine Alone or in Combination with Didanosine or Zalcitabine in HIV-Infected Patients with the Acquired Immunodeficiency Syndrome or Fewer Than 200 CD4 Cells per Cubic Millimeter
47. Phase 1 Study of Combination Therapy with L-697,661 and Zidovudine
48. A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
49. A Comparison of Immediate with Deferred Zidovudine Therapy for Asymptomatic HIV-Infected Adults with CD4 Cell Counts of 500 or More per Cubic Millimeter
50. Phase I/II Evaluation of Nevirapine Alone and in Combination with Zidovudine for Infection with Human Immunodeficiency Virus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.